VJHemOnc Podcast

Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception

Mar 22, 2024

Experts Stephen Ansell, Paolo Ghia, and Andrew Rawstron discuss Monoclonal B-cell lymphocytosis (MBL) as a precursor to CLL, exploring biology, classification, and early interception possibilities. They cover MBL progression, genetic similarities with CLL, B-cell receptor as an early marker, and the importance of immune system interactions for early intervention.

09:40

Creator website

Episode guests

Andrew Rawstron

Paolo Ghia

Stephen Ansell

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

High count MBL signifies progression to CLL, while low count MBL may relate to immunosenescence without evolving to CLL.

Presence of B-cell receptor years before CLL diagnosis indicates its role in early cell development towards CLL, emphasizing need for early interception strategies.

Deep dives

Monoclonal B Cell Lymphocytosis Classification

Monoclonal B cell lymphocytosis (MBL) is classified based on cell counts, with high count MBL showing a progression towards chronic lymphocytic leukemia (CLL) requiring treatment. Low count MBL, on the other hand, seems more related to immunosenescence, often existing in individuals above 40 years without progressing to CLL. Genetic aberrations are shared between low and high count MBL, but high count MBL have a higher likelihood of transforming into CLL and needing treatment.

Introduction

2min

Exploring Monoclonal B-cell Lymphocytosis Development and Classification

2min

Exploring the Progression of Monoclonal B-cell Lymphocytosis

2min

Progression and Early Markers in Monoclonal B-cell Lymphocytosis

2min

Exploring the Interaction Between MBL and the Immune System for Early Intervention

3min

Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment.

In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, Andrew Rawstron, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, and Anton Langerak, MD, PhD, Erasmus Medical Center and University, Rotterdam, The Netherlands, discuss the biology, classification, and possible interventions for MBL. This discussion took place at the 2024 Intercepting Blood Cancers Workshop in Lisbon, Portugal.

The post Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception appeared first on VJHemOnc.